3.4.21.108	medicine	amyloid beta, a pivotal factor implicated in the pathogenesis of Alzheimer´s disease interacts with HtrA2/Omi	670400	
3.4.21.108	medicine	critical role of HtrA2 in a cytokine-induced cell death response. Inhibition by a viral protein	689289	
3.4.21.108	medicine	heterozygous G399S mutation in Parkinson's disease patients, which is absent in healthy controls, a A141S polymorphism is associated with Parkinson's disease, both mutations result in defective activation of Omi/HtrA2 and mitochondrial dysfunction associated with altered mitochondrial morphology	668876	
3.4.21.108	medicine	HtrA2 is linked to cancer and neurodegeneration, like Alzheimers disease, Parkinsons disease, Huntingtons disease, and brain, kidney and myocardial ischemia, reperfusion	697488	
3.4.21.108	medicine	HtrA2 is linked to Parkinsons disease	697176	
3.4.21.108	medicine	HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. HtrA2 interacts with PINK1 and that both are components of the same stress-sensing pathway	689124	
3.4.21.108	medicine	HtrA2 knockout mice display features characteristic of a Parkinson syndrome, deletion of HtrA2 results in increased susceptibility to cell death stimuli, Smac/DIABOLO can compensate for the removal of HtrA2 in terms of neutralizing inhibitor of apoptosis proteins	670241	
3.4.21.108	medicine	HtrA2 under several different stress conditions induces cleavage of vimentin in wild-type as well as SH-SY5Y cells transfected with amyloid precursor protein with the Alzheimer disease-associated Swedish mutation. After stress treatment, inhibition of HtrA2 protease activity by the specific inhibitor, Ucf-101, reduces the cleavage of vimentin in wild-type cells	754775	
3.4.21.108	medicine	HtrA2-mediated proteolysis of WT1 may directly contribute to the effect of cytotoxic drugs warrants	717632	
3.4.21.108	medicine	HtrA2/Omi is associated with the pathogenesis of amyotrophic lateral sclerosis	710093